Prestige Consumer Healthcare (NYSE:PBH) Rating Reiterated by DA Davidson

Prestige Consumer Healthcare (NYSE:PBH)‘s stock had its “neutral” rating reiterated by equities researchers at DA Davidson in a research note issued on Thursday, Benzinga reports. They presently have a $65.00 target price on the stock. DA Davidson’s price target would suggest a potential downside of 0.49% from the company’s current price.

Other research analysts also recently issued research reports about the stock. TheStreet upgraded shares of Prestige Consumer Healthcare from a “c+” rating to a “b-” rating in a research report on Monday, February 12th. StockNews.com raised shares of Prestige Consumer Healthcare from a “buy” rating to a “strong-buy” rating in a report on Monday. Two research analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $95.00.

Prestige Consumer Healthcare Trading Down 1.7 %

Shares of PBH stock traded down $1.14 during mid-day trading on Thursday, reaching $65.32. The stock had a trading volume of 341,803 shares, compared to its average volume of 240,006. The stock’s 50-day moving average price is $71.02 and its two-hundred day moving average price is $65.19. Prestige Consumer Healthcare has a 52-week low of $55.96 and a 52-week high of $75.31. The firm has a market capitalization of $3.24 billion, a PE ratio of -39.83, a price-to-earnings-growth ratio of 1.91 and a beta of 0.53. The company has a current ratio of 3.09, a quick ratio of 1.92 and a debt-to-equity ratio of 0.75.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Tuesday, May 14th. The company reported $1.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.14 by ($0.12). The company had revenue of $277.00 million for the quarter, compared to analysts’ expectations of $287.42 million. Prestige Consumer Healthcare had a negative net margin of 7.11% and a positive return on equity of 14.09%. Prestige Consumer Healthcare’s quarterly revenue was down 3.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.07 EPS. Equities analysts expect that Prestige Consumer Healthcare will post 4.33 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several institutional investors have recently bought and sold shares of the business. Ariel Investments LLC increased its stake in Prestige Consumer Healthcare by 173.8% in the 3rd quarter. Ariel Investments LLC now owns 2,534,786 shares of the company’s stock worth $144,964,000 after buying an additional 1,609,044 shares during the period. Congress Asset Management Co. MA increased its position in Prestige Consumer Healthcare by 596.2% during the 4th quarter. Congress Asset Management Co. MA now owns 679,256 shares of the company’s stock valued at $41,584,000 after purchasing an additional 581,685 shares during the period. Norges Bank purchased a new position in Prestige Consumer Healthcare during the 4th quarter valued at about $27,739,000. Norden Group LLC increased its position in Prestige Consumer Healthcare by 1,593.7% during the 1st quarter. Norden Group LLC now owns 118,968 shares of the company’s stock valued at $8,632,000 after purchasing an additional 111,944 shares during the period. Finally, UBS Group AG increased its position in Prestige Consumer Healthcare by 377.6% during the 4th quarter. UBS Group AG now owns 131,382 shares of the company’s stock valued at $8,043,000 after purchasing an additional 103,872 shares during the period. Institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.